Although a recent study suggests that women with normal results on dual-energy X-ray absorptiometry (DXA) scans at ages 67 and older may wait up to 15 years for a second test, a Viewpoint article published today in the Journal of Bone and Mineral Research (JBMR) cautions that such a lengthy interval is inappropriate for many adults.
Viewpoints allow experts to provide a new perspective on research. In their article, osteoporosis experts Drs. E. Michael Lewiecki, Andrew Laster, Paul Miller and John Bilezikian write that monitoring bone mineral density by DXA should be done at intervals much shorter than 15 years for many individuals. These include younger postmenopausal women at high risk for fracture, patients whose DXA scans indicate bone mineral density values substantially below normal, those with prior fracture or clinical risk factors for fracture, and patients already receiving osteoporosis drug therapy.
The article comments on research recently published in the New England Journal of Medicine (NEJM.)
"Policy makers and patients who are concerned that over-use of medical tests may be driving up health care costs may be tempted to conclude that DXA scanning should be done less frequently," said Dr. Lewiecki. "In fact, just the opposite is true. Appropriate DXA screening reduces health care costs."
Many women, even those at risk for osteoporosis, never receive an initial DXA screening, the authors of the JBMR article note, with the result that osteoporosis often goes undiagnosed and untreated leading to debilitating fractures that are dangerous to patients and costly to treat. Over 200 million people worldwide suffer from osteoporosis, including 10 million Americans, with two million related fractures occurring annually and treatment costs exceeding $18 billion.
While the authors agree that a recommendation for extended intervals between bone mineral density tests is reasonable for women who fit the rather restricted profile in the NEJM study, physicians should not apply these recommendations to all postmenopausal women. Bone mineral density testing by DXA is the international standard for assessing skeletal health, the authors note, citing research from both the Geisinger Health System Osteoporosis Disease Management Program and Kaiser Permanente of Southern California, which found that increases in testing reduced fracture rates and associated health care costs.
"The JBMR has a responsibility to address important scientific and clinical issues regarding bone disease," concluded Dr. Thomas L. Clemens Editor-in-Chief of the JBMR. "As Dr. Lewiecki and colleagues point out, there are important limitations and exceptions to a recommendation of very long intervals between DXA testing"
Ben Norman | EurekAlert!
When a fish becomes fluid
17.12.2018 | Institute of Science and Technology Austria
Some brain tumors may respond to immunotherapy, new study suggests
11.12.2018 | Columbia University Irving Medical Center
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Materials Sciences
19.12.2018 | Materials Sciences
19.12.2018 | Life Sciences